<DOC>
	<DOCNO>NCT01752985</DOCNO>
	<brief_summary>The purpose study determine whether BMS-813160 reduce amount protein loss urine subject type 2 diabetes diabetic kidney disease</brief_summary>
	<brief_title>Study Evaluate Effects BMS-813160 Protein Loss Urine Subjects With Type 2 Diabetes Diabetic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Clinical diagnosis type 2 diabetes mellitus macroalbuminuria ( UACR 200 3500 mg/g ) Background angiotensin convert enzyme inhibitor ( ACEI ) angiotensinreceptor blocker ( ARB ) therapy Clinical diagnosis type 1 diabetes Unstable cardiovascular , metabolic , chronic disease status Estimated glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73 m2 High risk infection immune compromise Clinically significant ECG conduction abnormality Drugs significant potential affect BMS813160 exposure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>